Roivant Sciences Ltd.
ROIV
$20.81
-$0.06-0.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -45.13% | -35.86% | -11.19% | -40.27% | -29.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.13% | -35.86% | -11.19% | -40.27% | -29.51% |
| Cost of Revenue | 29.03% | 31.59% | 26.39% | 55.51% | 31.59% |
| Gross Profit | -35.43% | -37.64% | -29.48% | -57.61% | -30.40% |
| SG&A Expenses | 26.09% | 79.08% | 70.63% | 85.64% | 40.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.52% | 53.67% | 47.12% | 18.40% | -0.80% |
| Operating Income | -30.45% | -57.79% | -49.57% | -22.07% | -0.85% |
| Income Before Tax | -118.01% | -119.43% | -114.92% | -112.41% | 654.62% |
| Income Tax Expenses | -13.69% | 28.53% | 124.03% | -125.37% | 430.57% |
| Earnings from Continuing Operations | -118.90% | -120.42% | -116.05% | -112.33% | 645.04% |
| Earnings from Discontinued Operations | 426.88% | 297.95% | 218.37% | 225.43% | 40.84% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 40.60% | 65.28% | 56.94% | 97.17% | 48.84% |
| Net Income | -107.77% | -110.36% | -103.95% | -102.61% | 589.95% |
| EBIT | -30.45% | -57.79% | -49.57% | -22.07% | -0.85% |
| EBITDA | -32.04% | -61.03% | -53.22% | -22.64% | -1.13% |
| EPS Basic | -109.22% | -111.82% | -104.46% | -102.48% | 554.70% |
| Normalized Basic EPS | -72.14% | -82.61% | -29.31% | -8.88% | 27.13% |
| EPS Diluted | -109.92% | -112.63% | -104.84% | -102.68% | 527.71% |
| Normalized Diluted EPS | -76.15% | -87.26% | -29.81% | -9.20% | 28.79% |
| Average Basic Shares Outstanding | -9.22% | -8.48% | -7.40% | -1.51% | 4.03% |
| Average Diluted Shares Outstanding | -11.79% | -11.05% | -7.23% | -1.43% | 7.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |